Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S.
Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug ...